摘要
目的分析培美曲塞与吉西他滨分别联合顺铂治疗晚期非鳞非小细胞肺癌效果及对基质金属蛋白酶(MMP)及其抑制剂水平影响。方法对2013年1月至2015年12月诊治的晚期非鳞非小细胞肺癌患者进行研究,观察培美曲塞与吉西他滨分别联合顺铂治疗效果及对血清中基质金属蛋白酶及其抑制剂水平的影响。结果培美曲塞联合顺铂组患者的总有效率为56.0%,明显高于吉西他滨联合顺铂组的46.0%(P<0.01);治疗后两组患者的MMP2、MMP7、MMP9、基质金属蛋白酶抑制因子(TIMP)1、TIMP2、TIMP4蛋白水平均明显降低,且培美曲塞联合顺铂组患者的变化比吉西他滨联合顺铂组更显著,差异有统计学意义(P<0.01)。结论培美曲塞与吉西他滨分别联合顺铂对晚期非鳞非小细胞肺癌均有明显的效果,且前者有效率更高,治疗效果可能与其调节患者基质金属蛋白酶表达有关。
Objective The present research aimed to explore the effect of pemetrexed or gemcitabine combined cis - platinum on non - small cell lung cancer and its effect on the expression of MMP and TIMP. Methods 100 cases of non - small cell lung cancer patients in our hos-pital from Jan 2013 to Dec 2015 were enrolled in this research. The patients were divided into 2 groups, pemetrexed combined cis - platinum group and gemcitabine combined cis - platinum group. The efficiency of the two groups was assayed after medication. The serum inflammatory factors were also be detected. Results The results showed that pemetrexed combined cis - platinum group was more effective than gemcitabine combined cis - platinum group （ P 〈0.01）. The results also showed that the serum MMP2, MMP7, MMP9, TIMP1 , TIMP2, TIMP4 were decreased great-ly （ P 〈0. 01） . Conclusion Pemetrexed or gemcitabine combined cis - platinum cure the non - small cell lung cancer patients effectively and the former group shows a higher effective rate. The therapeutic effect may be related to its regulation of matrix metalloproteinase expression.
出处
《临床和实验医学杂志》
2017年第12期1193-1195,共3页
Journal of Clinical and Experimental Medicine
